Enveric Biosciences Inc. (NASDAQ: ENVB)
$0.3110
+0.0010 ( +2.64% ) 324.9K
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders. The company's lead program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. Enveric is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, being studied as a treatment of psychiatric disorders.
Market Data
Open
$0.3110
Previous close
$0.3100
Volume
324.9K
Market cap
$3.08M
Day range
$0.2950 - $0.3390
52 week range
$0.2955 - $2.9200
SEC Filings
Form Type | Description | Pages | Date |
---|---|---|---|
8-k | 8K-related | 13 | May 23, 2024 |
8-k | 8K-related | 13 | May 17, 2024 |
8-k | 8K-related | 15 | May 15, 2024 |
10-q | Quarterly Reports | 59 | May 15, 2024 |
8-k | 8K-related | 19 | May 03, 2024 |
def | Proxies and info statements | 5 | Apr 16, 2024 |
ars | Annual reports | 1 | Apr 16, 2024 |
8-k | 8K-related | 13 | Mar 28, 2024 |
10-k | Annual reports | 90 | Mar 26, 2024 |
8-k | 8K-related | 15 | Mar 26, 2024 |